Single Pass

Single Pass is addressing a critical complication in millions of annual solid organ biopsies: post-procedure hemorrhage. Their solution, the Kronos device, is a disposable, guide needle-compatible electrocautery tool that promises to reduce bleeding events, lower associated costs from transfusions and extended hospital stays, and enable the use of larger needles for better samples. With FDA approval secured and strong physician testimonials highlighting its ease of use and effectiveness, the company is positioned for commercialization in the hospital-based interventional radiology market. Leadership with deep medical device commercialization experience is guiding this transition from an innovative product to standard of care.

Disposable, battery-powered electrocautery system designed to seal and cauterize biopsy needle tracts through a co-axial guide needle.

Single Pass's Kronos device is currently presented as a first-in-class, patented solution with no direct competitors mentioned. It competes indirectly against traditional methods of bleeding control (pressure, hemostatic agents). Success will likely attract competition from established interventional device companies (e.g., Boston Scientific, Medtronic) who could develop similar or alternative tract-sealing technologies.